Skip to content
DataLookout
Menu

BLOSSOMNCT05835310

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Oct 1, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 25 versions: 24 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 103 → 111 locations
  2. Notable Eligibility criteria expanded, about 17 words Show 4 more changesShow less
    • Primary endpoints: details revised at 1 of 5 entries
    • Secondary endpoints: details revised at 2 of 11 entries
    • Site details revised at 3 of 103 sites
    • Study description expanded, about 5 words
  3. Minor Trial sites expanded: 100 → 103 locationsv24
  4. Minor Study sites: 99 to 100v23
  5. Notable Eligibility criteria expanded, about 108 words
    • Secondary endpoints: details revised at 1 of 11 entries
    v21
Show 19 earlier versionsHide 19 earlier versions
  1. Minor Study sites: 98 to 99v20
  2. Minor Study sites: 97 to 98v19
  3. Minor Study sites: 96 to 97v18
  4. Notable Eligibility criteria shortened, about 24 words
    • Study sites: 94 to 96
    • Secondary endpoints: 9 to 11
    v17
  5. Minor Study sites: 92 to 94v16
  6. Notable Eligibility criteria expanded, about 8 wordsv15 Show 5 more changesShow less
    • Primary endpoints: 7 to 5
    • Study completion date: Mar 12, 2030 to Jan 9, 2030
    • Secondary endpoints revised (9)
    • Study description revised
    • Site details revised at 3 of 92 sites
  7. Minor Site details revised at 4 of 92 sitesv14
  8. Minor Primary completion date: Jul 25, 2029 to Oct 5, 2028
    • Site details revised at 3 of 92 sites
    v13
  9. Minor Site details revised at 3 of 92 sitesv12
  10. Minor Site details revised at 2 of 92 sitesv11
  11. Notable Trial status: Active, Not Recruiting to Recruiting
    • Study sites: 87 to 92
    v10
  12. Minor Study sites: 88 to 87v9
  13. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 92 to 88
    v8
  14. Minor Site details revised at 10 of 92 sitesv7
  15. Minor Site details revised at 2 of 92 sitesv6
  16. Minor Site details revised at 13 of 92 sitesv5
  17. Minor Study sites: 81 to 92
    • Study completion date: May 21, 2030 to Mar 12, 2030
    v4
  18. Notable Eligibility criteria expanded, about 51 wordsv3 Show 4 more changesShow less
    • Study sites: 77 to 81
    • Study completion date: Jan 15, 2030 to May 21, 2030
    • Secondary endpoints: 8 to 9
    • Study description expanded, about 8 words
  19. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Start date changed from estimate of Jun 21, 2023 to Mar 14, 2024
    • Study sites: 0 to 77
    • Primary completion date: Oct 9, 2029 to Jul 25, 2029
    • Study completion date: Oct 9, 2029 to Jan 15, 2030
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Part A- Anifrolumab serum concentration
Timeframe: Pre-dose Day 29
Part A - Maximum observed serum (peak) drug concentration (Cmax)
Timeframe: Up to Day 29
Part A - Area under the serum concentration curve (AUC)
Timeframe: Up to Day 29
Part A - Minimum observed serum concentration (Cmin)
Timeframe: Up to Day 29
Part B - Number of participants who are British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) responders (yes/no)
Timeframe: At Week 52

Secondary (11)

Part B - Number of participants who are Systemic Lupus Erythematosus Responder Index of ≥ 4 SRI(4) responders (yes/no)
Part B - Time to first flare
Part B - Anifrolumab serum concentration
Part - B Change from baseline through Week 52 in antidrug antibody (ADA)
Part - B Change from baseline in anti-double stranded deoxyribonucleic acid antibodies
Show 6 moreShow less
Part - B Change from baseline in total hemolytic complement (CH50)
Part - B Change from baseline in complement component (C3)
Part - B Change from baseline in complement component (C4)
Number of participants who are Pediatric Rheumatology International Trials Organization/American College of Rheumatology (PRINTO/ACR) childhood-onset systemic lupus erythematosus (cSLE) responders (yes/no)
Part B - The mean percentage reduction from Baseline through Week 52 in oral corticosteroid(s) (OCS) background dose
Part B - Change from baseline through Week 52 in type I interferon (IFN) 21-gene signature

Arms and interventions

AnifrolumabExperimental

Randomized participants will receive anifrolumab via intravenous (IV) infusion every 4 weeks

PlaceboPlacebo comparator

Randomized participants will receive matching placebo via IV infusion

Biologicals: Anifrolumab

Drugs: Placebo

Sites

111 sites in 18 countries

United States 23, Japan 13, China 11, Brazil 7, Spain 7, United Kingdom 7, Italy 6, France 5, Mexico 5, Argentina 4, South Africa 4, Turkey (Türkiye) 4, Canada 3, Germany 3, Poland 3, Portugal 3, Colombia 2, Taiwan 1